10X Genomics (TXG)
NASDAQ:TXG
TXG Stock Chart & Stats
$23.27
-$0.12(-0.77%)
At close: 4:00 PM EST
$23.27
-$0.12(-0.77%)
Day’s Range― - ―
52-Week Range$7.25 - $23.65
Previous CloseN/A
Volume385.49K
Average Volume (3M)2.16M
Market Cap
$2.97B
Enterprise Value$2.66B
Total Cash (Recent Filing)$523.41M
Total Debt (Recent Filing)$157.74M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding117,673,386
10 Day Avg. Volume1,946,591
30 Day Avg. Volume2,158,576
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue4.13
Enterprise Value/Gross Profit5.98
Enterprise Value/Ebitda-211.97
Forecast
1Y Price Target
$20.46Price Target Upside-12.08% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$612.57M
Bulls Say, Bears Say
Bulls Say
AI Partnerships And Spatial Data ValidationCollaborations with major research initiatives and selection of the Xenium platform for a large clinically linked spatial biology atlas validate the company's ability to generate high-quality, AI-scale biological datasets that can attract long-term demand for its platforms.
Consumables Growth Driven By New Product AdoptionSolid adoption of the Flex Apex assay and rising Xenium utilization are increasing consumables volumes as customers run more advanced experiments, supporting recurring revenue expansion.
Profitability And Financial FlexibilityAdjusted EBITDA reaching breakeven and reduced inventory write-downs improved margins and provide stronger financial flexibility to support investment in product rollouts and market expansion, according to analysts.
Bears Say
Academic Funding And Grant Activity RiskChallenged grant activity and a softer academic market create downside risk to consumables demand and overall sales in core research channels.
Muted Instrument Placements And Constrained CapexConstrained lab budgets and deliberate customer purchasing are keeping instrument placements muted, limiting growth of the installed base that drives future consumable sales.
Pricing Pressure And Unfavorable Product MixIntroduction of lower-priced products and pricing pressure on flagship consumables are offsetting volume gains and limiting revenue per experiment.
10x Genomics News
TXG FAQ
What was 10X Genomics’s price range in the past 12 months?
10X Genomics lowest stock price was $7.25 and its highest was $23.65 in the past 12 months.
What is 10X Genomics’s market cap?
10X Genomics’s market cap is $2.97B.
When is 10X Genomics’s upcoming earnings report date?
10X Genomics’s upcoming earnings report date is May 06, 2026 which is in 23 days.
How were 10X Genomics’s earnings last quarter?
10X Genomics released its earnings results on Feb 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.203 by $0.073.
Is 10X Genomics overvalued?
According to Wall Street analysts 10X Genomics’s price is currently Overvalued.
Does 10X Genomics pay dividends?
10X Genomics does not currently pay dividends.
What is 10X Genomics’s EPS estimate?
10X Genomics’s EPS estimate is -0.27.
How many shares outstanding does 10X Genomics have?
10X Genomics has 117,673,386 shares outstanding.
What happened to 10X Genomics’s price movement after its last earnings report?
10X Genomics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.203. Following the earnings report the stock price went up 3.484%.
Which hedge fund is a major shareholder of 10X Genomics?
Currently, no hedge funds are holding shares in TXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.46 (-12.08% Downside)
$20.46 (-12.08% Downside)
Blogger Sentiment
Neutral
TXG Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $490.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
202.20%
12-Months-Change
Fundamentals
Return on Equity
-5.69%
Trailing 12-Months
Asset Growth
13.36%
Trailing 12-Months
Company Description
10X Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
TXG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong operational and commercial progress in consumables, reaction volumes, product innovation (notably FLEX APEX and Xenium), improved gross margin, and a materially stronger cash position were clear positives. Offsetting these wins were meaningful declines in instrument revenue, continued capital expenditure constraints, regional funding variability (notably the Americas), and pricing/mix considerations from lower-cost assays. Management reinstated cautious but constructive guidance for 2026 (flat-to-modest growth excluding settlements) and emphasized continued cost discipline.View all TXG earnings summariesTXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
TXG Stock 12 Month Forecast
Average Price Target
$20.46
▼(-12.08% Downside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―
Ownership Overview
2.52% Insiders
24.82% Mutual Funds
34.10% Other Institutional Investors
12.85% Public Companies and
Individual Investors